Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it needs to take early stage companies through development, which is what it will take to really boost the ecosystem.

The onus is on players across the spectrum, including investors, entrepreneurs and academic leaders, to capitalize on the momentum...